Blade Therapeutics Overview

  • Status
  • Private
  • Employees
  • 26
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $50M
Latest Deal Amount
  • Investors
  • 10

Blade Therapeutics General Information

Description

Developer of novel anti-fibrotic therapies designed to revolutionize the treatment of fibrotic disease. The company's therapies address various fibrotic diseases and their underlying pathophysiology to potentially reverse the fibrotic damage to tissue, enabling patients to get cured of the disease without any side effects.

Contact Information

Formerly Known As
FibroRX
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 442 Littlefield Avenue
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

Blade Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Blade Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series C) 23-Oct-2019 $50M 00000 00000 Completed Clinical Trials - Phase 1
7. Debt - General 08-Mar-2019 0000 000.00 Completed Clinical Trials - Phase 1
6. Accelerator/Incubator 000.00 Completed Clinical Trials - Phase 1
5. Accelerator/Incubator 30-Jun-2016 000.00 Completed Clinical Trials - Phase 1
4. Early Stage VC (Series B) 08-Jun-2016 0000 000.00 000.00 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 06-Jul-2015 000 00.00 0000 Completed Clinical Trials - Phase 1
2. Debt - General 01-May-2015 $500K $500K Completed Clinical Trials - Phase 1
1. Early Stage VC 01-Oct-2013 Completed Startup
To view Blade Therapeutics’s complete valuation and funding history, request access »

Blade Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C-1 00,000,000 00.000000 00.0 00.00 00.00 00 00.00 00
Series C 00,000,000 00.000000 00.0 00.00 00.00 00 00.00 00.000
Series B 43,000,000 $0.000100 $0.07 $1.05 $1.05 1x $1.05 39.26%
Series A 6,500,000 $0.000100 $0.09 $1 $1 1x $1 5.93%
To view Blade Therapeutics’s complete cap table history, request access »

Blade Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel anti-fibrotic therapies designed to revolutionize the treatment of fibrotic disease. The company's th
Drug Discovery
South San Francisco, CA
26 As of 2021
00000
0000 0000-00-00
00000000000 00000

0000000

eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud e
0000 000000000
Boston, MA
0 As of 0000
00000
000000000 00000

00000000

nsectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut eni
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Blade Therapeutics Competitors (40)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aileron Therapeutics Formerly VC-backed Boston, MA 0 00000 000000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000000 Formerly VC-backed Ballerup, Denmark 000 00000 000000&0 00000
0000000 0000000000 Formerly VC-backed Toronto, Canada 0 00.000 000000&0 00.000
00 0000000 Venture Capital-Backed Copenhagen N, Denmark 00 00000 00000000000 00000
You’re viewing 5 of 40 competitors. Get the full list »

Blade Therapeutics Executive Team (15)

Name Title Board Seat Contact Info
Wendye Robbins MD President, Board Member and Chief Executive Officer
Prabha Ibrahim Ph.D Chief Technology Officer
Joel Outten Associate Director, Business Intelligence
Felix Karim Ph.D Executive Vice President, Business Development
Maria Fuentes Ph.D Executive Vice President, Research
You’re viewing 5 of 15 executive team members. Get the full list »

Blade Therapeutics Board Members (11)

Name Representing Role Since
Cameron Wheeler Ph.D Deerfield Management Board Member 000 0000
James Scopa JD MPM Capital Board Member 000 0000
Lloyd Klickstein Ph.D Self Board Member 000 0000
Luke Evnin Ph.D MPM Capital Board Member 000 0000
Mark Timney Self Chairman 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Blade Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Blade Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
JLABS Accelerator/Incubator 000 0000 000000 0
OneVentures Venture Capital Minority 000 0000 000000 0
Bristol-Myers Squibb Corporation Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
Novartis Institutes for BioMedical Research Corporation Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Blade Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 25-Sep-2019 000000000000000000 Biotechnology 000000 0000000 00
To view Blade Therapeutics’s complete acquisitions history, request access »